Conversely, sequential treatment with CDK6 inhibitors following DNA-damaging chemotherapy was shown to improve the therapeutic effect in pancreatic cancer, which was due to the action of CDK6 inhibitors on the homologous recombinant proteins responsible for repairing chromosome damage (25). Here, CDK6 is linked to familial pancreatic carcinoma.